<DOC>
	<DOCNO>NCT02101073</DOCNO>
	<brief_summary>The overall aim study : - To assess bioavailability single dose ALX-0061 , administer s.c. three dose level , use 2 correspond single i.v . dose level reference . - To provide additional information pharmacokinetics pharmacodynamics ALX-0061 . - To determine safety tolerability ALX-0061 . - To evaluate systemic ( serum ) immunogenicity ALX-0061 .</brief_summary>
	<brief_title>ALX-0061 Phase I Bioavailability Study Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Key 1 . Healthy volunteer . 2 . Gender : male female . 3 . Age 18 55 year . 4 . Body mass index ( BMI ) : 18.0 â‰¥ BMI &lt; 30.0 kg/m2 . Key 1 . Any active inflammatory condition , autoimmune disorder lupus erythematosus , multiple sclerosis rheumatoid arthritis ( RA ) . 2 . Any current recent ( within 4 week prior dose ) sign symptoms infection require parenteral antibiotic administration . 3 . Symptomatic infection , suspicion thereof last 1 week prior dosing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>